Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

170.17USD
19 Dec 2014
Price Change (% chg)

$1.69 (+1.00%)
Prev Close
$168.48
Open
$168.15
Day's High
$171.72
Day's Low
$167.49
Volume
4,625,473
Avg. Vol
1,702,250
52-wk High
$173.14
52-wk Low
$108.24

AMGN.OQ

Chart for AMGN.OQ

About

Amgen Inc. (Amgen) is a global biotechnology company that discovers, develops, manufactures and delivers human therapeutics. It focuses its research and development activities on human therapeutics for in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular and general medicine, which... (more)

Overall

Beta: 0.52
Market Cap (Mil.): $119,820.70
Shares Outstanding (Mil.): 760.67
Dividend: 0.79
Yield (%): 2.01

Financials

  AMGN.OQ Industry Sector
P/E (TTM): 24.79 38.19 38.61
EPS (TTM): 6.35 -- --
ROI: 8.54 19.00 18.27
ROE: 20.76 19.75 19.14
Search Stocks

Exclusive: Express Scripts presses for expansion of drugs it won't cover

LOS ANGELES - Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year.

23 Dec 2014

Express Scripts presses for more drug savings with coverage list

LOS ANGELES - Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year.

23 Dec 2014

Exclusive: Express Scripts presses for more drug savings with coverage list

LOS ANGELES - Express Scripts , the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year.

23 Dec 2014

Exclusive: Amgen's new leukemia drug to carry $178,000 price tag

- Amgen Inc on Wednesday said its new type of treatment for a deadly form of leukemia would cost about $178,000 when it becomes available on Thursday, which would make it one of the world's most expensive cancer drugs.

17 Dec 2014

CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, Celgene

(Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)

08 Dec 2014

Addition of Amgen drug boosts benefits in relapsed myeloma: study

- Significantly more patients with relapsed multiple myeloma responded to a three-drug regimen including Amgen Inc's Kyprolis than those who got the standard two-drug treatment, according to results from a late-stage trial.

06 Dec 2014

Addition of Amgen drug boosts benefits in relapsed myeloma -study

Dec 6 - Significantly more patients with relapsed multiple myeloma responded to a three-drug regimen including Amgen Inc's Kyprolis than those who got the standard two-drug treatment, according to results from a late-stage trial.

06 Dec 2014

Sandoz loses bid to shield psoriasis drug

- The top U.S. patent appeals court has upheld the dismissal of a lawsuit brought by Sandoz Inc that sought to shield its planned version of Amgen Inc's psoriasis and arthritis drug Enbrel from patent lawsuits.

05 Dec 2014

Sandoz loses bid to shield psoriasis drug

- The top U.S. patent appeals court has upheld the dismissal of a lawsuit brought by Sandoz Inc that sought to shield its planned version of Amgen Inc's psoriasis and arthritis drug Enbrel from patent lawsuits.

05 Dec 2014

Sandoz loses bid to shield psoriasis drug

Dec 5 - The top U.S. patent appeals court has upheld the dismissal of a lawsuit brought by Sandoz Inc that sought to shield its planned version of Amgen Inc's psoriasis and arthritis drug Enbrel from patent lawsuits.

05 Dec 2014

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00
Provider: Directors Deals Ltd.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks